Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00667953 · ClinicalTrials.gov registry record · Phase 1
Study of Temzolomide and Gleevec in Advanced Melanoma
A Phase 1 study, sponsored by Abramson Cancer Center at Penn Medicine.
- Terminated
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT00667953 is a Phase 1 study that was terminated before completion, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 32 participants.
The verdict
NCT00667953, a Phase 1 study, was terminated before completion, sponsored by Abramson Cancer Center at Penn Medicine.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This study has been designed to evaluate the side effects of Gleevec when given in combination with Temzolomide; and to learn more about how these drugs work in the body and whether this combination is useful in treating patients with melanoma.
Interventions
- DRUG Gleevec
- DRUG Temodar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2003-01 |
| Est. Completion | 2011-03-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00667953
The ClinicalTrials.gov registry entry for NCT00667953 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Gleevec is the first listed.
NCT00667953 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00667953 about?
NCT00667953 is a clinical study titled "Study of Temzolomide and Gleevec in Advanced Melanoma". This study has been designed to evaluate the side effects of Gleevec when given in combination with Temzolomide; and to learn more about how these drugs work in the body and whether this combination is useful in treating patients with melanoma.
What is the current status of trial NCT00667953?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2003-01. Estimated completion is 2011-03-09.
What interventions are being tested in trial NCT00667953?
The interventions under investigation include: Gleevec (DRUG), Temodar (DRUG).
Who is sponsoring clinical trial NCT00667953?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.